FLT3 and acute myeloid leukemia: It is known to significantly improve overall survival when added to standard induction and consolidation therapy in FLT3 mutated AML patients.[14] Since our patient harbored FLT3-ITD mutation, midostaurin was used in creative combination with backbone chemotherapy depending on the patient's condition to control AML (Fig. 5).